Where Will Bluebird Bio Be in 1 Year?
The past few years have been harsh on Bluebird Bio (NASDAQ: BLUE). The rare-diseases-focused, gene-therapy specialist ran into a series of clinical and regulatory headwinds, which played a major role in its catastrophic performance in the stock market since 2019. Bluebird's shares have dropped by almost 97% in the past three years.
That said, there may be some reason for optimism. The company is awaiting word from regulators in the U.S. for a couple of promising gene-editing therapies. If both are approved, Bluebird's fortunes could improve drastically. However, if the biotech runs into even more headwinds, investors who get in on the action today could be left with worthless shares.
With that as a backdrop, let's look into what could transpire for Bluebird in the next year.
Source Fool.com
